European Medicines Agency

XTANDI (Enzalutamide) Has Been Authorized in the European Union (EU) for Advanced Prostate Cancer

The great news for for our brothers in Europe is that Xtandi (Enzalutamide) has been approved for use in the European Union (EU) for the treatment of men with metastatic castration-resistant prostate cancer whose disease has progressed on or after chemotherapy (docetaxel). Following the regulatory review process by the European Medicines Agency (EMA) and a [...]

By Malecare|2017-10-19T10:49:42-04:00July 5th, 2013|Advanced Prostate Cancer, CHMP, enzalutamide, Enzalutamide (MDV-3100), European Union, General Information, MDV3100, Politics of Cancer, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Xtandi|0 Comments

CHMP Makes A Positive Recommendation on the Use of Xtandi

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted approval of Xtandi in the treatment of men with castrate resistant prostate cancer that has progressed after the use of chemotherapy. It has already been approved for use in the United States. Xtandi (aka Enzalutamide and MDV3100) is a strong androgen [...]